Breaking News Instant updates and real-time market news.

DXCM

Dexcom

$67.47

-0.45 (-0.66%)

, ABT

Abbott

$52.15

-0.7 (-1.32%)

08:02
09/28/17
09/28
08:02
09/28/17
08:02

Dexcom price target lowered to $76 from $85 at Wedbush

Wedbush analyst Tao Levy lowered his price target for Dexcom (DXCM) to $76 from $85 due to Abbott (ABT) obtaining FDA approval of its FreeStyle Libre CGM sooner and with a better label than anticipated. Nonetheless, the analyst reiterates an Outperform rating on Dexcom's shares as he believes the market opportunity is large enough to support more than one company and Dexcom's G5 CGM offers users several unique advantages that will continue to attract new users to its system. Further, Levy believes Dexcom could accelerate its own no-calibration CGM regulatory program and potentially obtain FDA approval by the end of 2018.

DXCM

Dexcom

$67.47

-0.45 (-0.66%)

ABT

Abbott

$52.15

-0.7 (-1.32%)

  • 18

    Oct

DXCM Dexcom
$67.47

-0.45 (-0.66%)

09/28/17
PIPR
09/28/17
NO CHANGE
Target $87
PIPR
Overweight
Abbott approval an incremental negative for Dexcom, says Piper Jaffray
Piper Jaffray analyst Matt O'Brien says Abbott's (ABT) FDA approval of its Libre glucose monitor is "clearly" a negative for Dexcom (DXCM). Abbott was able to get some type of dosing claim, making its glucose monitor "a bit more of a perceived threat" than anticipated, O'Brien tells investors in a research note. He believes the Libre approval and now dosing claim will "hang over" Dexcom through the remainder of the year, making it "difficult for the stock to work in the near term." O'Brien, however, continues to believe Dexcom has the best CGM technology out there. He encourages long-term investors to build positions on today's weakness and keeps an Overweight rating on the shares with an $87 price target. JPMorgan this morning downgraded Dexcom to Neutral.
09/28/17
RAJA
09/28/17
DOWNGRADE
RAJA
Market Perform
Dexcom downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Jayson Bedford downgraded DexCom (DXCM) to Market Perform from Outperform citing increased competitive concerns. The analyst said Abbott's (ABT) Libre device was expected to be approved by the FDA, but the broader label, that includes a dosing claim, was not. Bedford expects Libre to receive Medicare reimbursement and for Abbott to be more aggressive on pricing, impacting DexCom's growth outlook.
09/28/17
OPCO
09/28/17
NO CHANGE
Target $85
OPCO
Outperform
Dexcom price target lowered to $85 from $92 at Oppenheimer
Oppenheimer analyst Steven Lichtman lowered his price target for Dexcom (DXCM) to $85 from $92 after Abbott (ABT) Libre glucose monitoring system received FDA approval including a dosing claim. The dosing claim along with Libre's already known no calibration requirement could create a near-term new patient acquisition headwind for Dexcom, he contends. While Lichtman believes yesterday's news to be a near-term negative for Dexcom, he recommends buying on weakness with new drivers ahead. He reiterates an Outperform rating on Dexcom's shares.
09/28/17
SPHN
09/28/17
NO CHANGE
Target $70
SPHN
Overweight
Abbott Libre dosing claim a 'black swan event' for Dexcom, says Stephens
While Abbott (ABT) receiving FDA approval of it FreeStyle Libre glucose monitor was "fully expected," the apparent dosing claim for adult patients was a "black swan event," said Stephens analyst Chris Cooley, who cut his price target on Dexcom (DXCM) to $70 from $83 after the unexpected news. He keeps an Overweight rating on Dexcom shares, though, as he sees the CY18 outlook as challenged but thinks the company will be able to ultimately re-accelerate top-line growth given the expected clearance of G6 and user preference for accuracy and functional CGM data.
ABT Abbott
$52.15

-0.7 (-1.32%)

09/28/17
WELS
09/28/17
NO CHANGE
Target $64
WELS
Outperform
Abbott price target raised to $64 from $57 at Wells Fargo
Wells Fargo analyst Lawrence Biegelsen raised his price target for Abbott to $64 from $57, citing increased conviction in the 2H outlook and its 2018 prospects after meeting with management. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

03:30
02/22/18
02/22
03:30
02/22/18
03:30
General news
FX Action: USD-CAD clocked a two-month high »

FX Action: USD-CAD…

JELD

Jeld-Wen

$34.50

-3.14 (-8.34%)

03:27
02/22/18
02/22
03:27
02/22/18
03:27
Downgrade
Jeld-Wen rating change  »

Jeld-Wen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Mar

ALKS

Alkermes

$63.19

-1.56 (-2.41%)

03:27
02/22/18
02/22
03:27
02/22/18
03:27
Downgrade
Alkermes rating change  »

Alkermes downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSA

MSA Safety

$80.25

3.79 (4.96%)

03:25
02/22/18
02/22
03:25
02/22/18
03:25
Upgrade
MSA Safety rating change  »

MSA Safety upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

02:50
02/22/18
02/22
02:50
02/22/18
02:50
General news
FX Update: The dollar has continued to mostly trade firmer »

FX Update: The dollar…

02:15
02/22/18
02/22
02:15
02/22/18
02:15
General news
Asian Market Summary: »

Asian Market Summary:…

00:00
02/22/18
02/22
00:00
02/22/18
00:00
General news
Breaking General news story  »

Federal Reserve Vice…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

, HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

20:25
02/21/18
02/21
20:25
02/21/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

APA

Apache

$37.20

-1.1 (-2.87%)

LDOS

Leidos

$65.21

-1.02 (-1.54%)

W

Wayfair

$95.69

-0.61 (-0.63%)

OA

Orbital ATK

$131.80

-0.02 (-0.02%)

TREE

LendingTree

$371.25

-7.8 (-2.06%)

SFM

Sprouts Farmers Market

$26.12

0.12 (0.46%)

TPX

Tempur Sealy

$54.97

1.17 (2.17%)

SAFM

Sanderson Farms

$128.00

-3.44 (-2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 28

    Feb

  • 07

    Mar

  • 08

    Mar

  • 20

    Mar

  • 29

    Mar

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

20:04
02/21/18
02/21
20:04
02/21/18
20:04
Syndicate
Aimmune 5.5M share Secondary priced at $32.00 »

BofA/Merrill, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 11

    Mar

  • 22

    Feb

20:00
02/21/18
02/21
20:00
02/21/18
20:00
General news
Breaking General news story  »

Minneapolis Federal…

NUAN

Nuance

$16.28

-0.28 (-1.69%)

19:10
02/21/18
02/21
19:10
02/21/18
19:10
Periodicals
Nuance discontinues Swype feature development, Verge reports »

Nuance has ceased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SSNLF

Samsung

, QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

19:04
02/21/18
02/21
19:04
02/21/18
19:04
Hot Stocks
Samsung, Qualcomm expand foundry cooperation on EUV process technology »

Samsung Electronics…

SSNLF

Samsung

QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

CATY

Cathay General

$42.84

0.43 (1.01%)

18:59
02/21/18
02/21
18:59
02/21/18
18:59
Hot Stocks
Cathay General executive chairman Cheng sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$30.00

-0.08 (-0.27%)

18:42
02/21/18
02/21
18:42
02/21/18
18:42
Earnings
Sunoco reports Q4 EPS $2.01, may not compare to consensus 35c »

Reports Q4 revenue $3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

USFD

US Foods

$32.29

0.33 (1.03%)

18:39
02/21/18
02/21
18:39
02/21/18
18:39
Hot Stocks
US Foods director Lederer sells 98,702 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:38
02/21/18
02/21
18:38
02/21/18
18:38
Earnings
Volaris reports Q4 28c, consensus 20c »

Reports Q4 revenue $336M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:34
02/21/18
02/21
18:34
02/21/18
18:34
Earnings
Breaking Earnings news story on Volaris »

Volaris reports Q4 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VMI

Valmont

$156.55

-0.55 (-0.35%)

18:29
02/21/18
02/21
18:29
02/21/18
18:29
Earnings
Valmont sees 2018 adjusted $8.00, consensus $8.15 »

Sees 2018 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

VMI

Valmont

$156.55

-0.55 (-0.35%)

18:27
02/21/18
02/21
18:27
02/21/18
18:27
Earnings
Valmont reports Q4 adjusted EPS $1.67, consensus $1.69 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 06

    Mar

CTRV

ContraVir Pharmaceuticals

$0.25

-0.013 (-5.00%)

18:11
02/21/18
02/21
18:11
02/21/18
18:11
Hot Stocks
ContraVir Pharmaceuticals' hepatitis B treatment receives FDA Orphan designation »

ContraVir…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

AAC

AAC Holdings

$8.38

0.25 (3.08%)

18:06
02/21/18
02/21
18:06
02/21/18
18:06
Earnings
AAC Holdings sees FY18 adjusted EPS 70c-75c, consensus 53c »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

AAC

AAC Holdings

$8.38

0.25 (3.08%)

18:05
02/21/18
02/21
18:05
02/21/18
18:05
Earnings
AAC Holdings reports Q4 adjusted EPS 10c, consensus 4c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

DNKN

Dunkin' Brands

$60.70

-1.45 (-2.33%)

18:04
02/21/18
02/21
18:04
02/21/18
18:04
Hot Stocks
Baskin-Robbins expands in Toronto with plans for four new locations »

Baskin-Robbins, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$102.43

0.05 (0.05%)

18:01
02/21/18
02/21
18:01
02/21/18
18:01
Hot Stocks
Celanese to increase price of acetyl intermediate products »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 30

    May

TUSK

Mammoth Energy

$20.04

-0.11 (-0.55%)

17:56
02/21/18
02/21
17:56
02/21/18
17:56
Earnings
Mammoth Energy reports Q4 EPS $1.48, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.